A study to capture the side effects and Quality of life(QoL) in castration-resistant prostate cancer patients who are receiving docetaxel as part of standard therapy in Tata Memorial Centre.
Not Applicable
- Conditions
- Health Condition 1: C61- Malignant neoplasm of prostate
- Registration Number
- CTRI/2019/09/021080
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patient of either gender aged 18 or more than 18
2. Metastatic Prostate Carcinoma patients receiving docetaxel chemotherapy.
Exclusion Criteria
1. Patient not willing to give consent.
2. Patients having non-compliance to the treatment schedule at Tata memorial Hospital or ACTREC.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse Drug ReactionTimepoint: 2 Weekly- 3 Weekly
- Secondary Outcome Measures
Name Time Method Causality assessment of the adverse reactionsTimepoint: 2 Weekly- 3 Weekly;Grade III and Grade IV adverse eventsTimepoint: 2 Weekly- 3 Weekly;quality of lifeTimepoint: 2-3 Monthly